Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 4, Pages 575-586Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.21
Keywords
cytokine; glioblastoma; intracellular signaling; JAK/STAT; NF-kappa B
Categories
Funding
- American Cancer Society [CA-97247, NS-50665, IRG-60-001-47]
- NCI [CA-13148-31]
- UAB Comprehensive Cancer Center (ENB) [NIH CA-13148-35, P30 CA-13149-38]
- Southeastern Brain Tumor Foundation (SEN)
- UAB Medical Scientist Training Program
- NIH [T32-AI0705]
Ask authors/readers for more resources
Glioblastoma remains the most clinically challenging tumor of the CNS, as evidenced by the dismal change in overall survival over the past 50 years. However, recent advances in high-throughput screening techniques have given rise to a wealth of new information regarding the aberrant signaling pathways that drive the tumor phenotype. Two of these so-called 'oncopathways' are NF-kappa B and JAK/STAT. This review will describe the basic mechanisms of these pathways, explore the relevance of NF-kappa B and JAK/STAT signaling in glioblastoma, and look ahead to experimental compounds that will integrate our knowledge of these pathways into existing therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available